Terlipressin use in hepatorenal syndrome-acute kidney injury in cirrhosis

Affiliations

¹ Department of Medicine, University of Toronto, Toronto General Hospital, Toronto, ON, Canada. Florence.wong@utoronto.ca.
² Orphan Therapeutics LLC, Long Boat Key, FL, USA.

Florence Wong et al. Intensive Care Med. 2025 Jan.

. 2025 Jan;51(1):213-214.

doi: 10.1007/s00134-024-07681-4. Epub 2024 Oct 23.

¹ Department of Medicine, University of Toronto, Toronto General Hospital, Toronto, ON, Canada. Florence.wong@utoronto.ca.
² Orphan Therapeutics LLC, Long Boat Key, FL, USA.

No abstract available

Conflict of interest statement

Declarations. Conflict of interest: The authors declare that they have no conflict of interest.

1. Nadim MK, Forni LG, Ostermann M, The ADQI 29/ICA Expert Panel (2024) Hepatorenal syndrome in the intensive care unit. Intensive Care Med 50:978–981 - DOI - PubMed
1. Nadim MK, Forni LG, Ostermann M, The ADQI 29/ICA Expert Panel (2024) Terlipressin use in HRS-AKI and respiratory failure. Intensive Care Med. https://doi.org/10.1007/s00134-024-07585-3 - DOI - PubMed - PMC
1. Arrestier R, Billiet PA, Frapard T, Dessap AM (2024) Terlipressin use in HRS-AKI and respiratory failure. Intensive Care Med. https://doi.org/10.1007/s00134-024-07556-8 - DOI - PubMed
1. Nadim MK, Kellum JA, Forni L et al (2024) Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. J Hepatol 81:163–183 - DOI - PubMed - PMC
1. Ma AT, Juanola A, Solé C, Ginès P (2024) Shortening the albumin challenge from 48 to 24 hours may lead to overdiagnosis of hepatorenal syndrome-acute kidney injury and overtreatment with terlipressin. J Hepatol. https://doi.org/10.1016/j.jhep.2024.07.015 - DOI - PubMed